Table 5.

The association of discharge lipid-lowering therapy (LLT) and outcomes

	Total	Events (n%)	HR (95% CI) unadjusted	P value	HR (95% CI) adjusted	P value
3 months
Stroke recurrence
Discharge LLT	13 248	269 (2.0)	0.68 (0.48 to 0.96)	0.03	0.69 (0.48 to 0.99)	0.04
Non-discharge LLT	1181	35 (3.0)	Reference		Reference
Ischaemic stroke
Discharge LLT	13 263	245 (1.9)	0.68 (0.47 to 0.98)	0.04	0.65 (0.45 to 0.94)	0.02
Non-discharge LLT	1188	32 (2.7)	Reference		Reference
Haemorrhagic stroke
Discharge LLT	13 740	31 (0.2)	0.71 (0.25 to 2.01)	0.52	1.19 (0.36 to 3.98)	0.78
Non-discharge LLT	1266	4 (0.3)	Reference		Reference
MACE
Discharge LLT	13 248	299 (2.3)	0.71 (0.51 to 1.003)	0.052	0.74 (0.52 to 1.04)	0.08
Non-discharge LLT	1181	37 (3.1)	Reference		Reference
12 months
Stroke recurrence
Discharge LLT	13 248	758 (5.7)	0.88 (0.7 to 1.12)	0.30	0.89 (0.7 to 1.14)	0.36
Non-discharge LLT	1181	75 (6.4)	Reference		Reference
Ischaemic stroke
Discharge LLT	13 263	683 (5.2)	0.87 (0.68 to 1.11)	0.26	0.86 (0.67 to 1.10)	0.23
Non-discharge LLT	1188	69 (5.8)	Reference		Reference
Haemorrhagic stroke
Discharge LLT	13 740	86 (0.6)	0.97 (0.47 to 2.00)	0.94	1.23 (0.56 to 2.69)	0.60
Non-discharge LLT	1266	8 (0.6)	Reference		Reference
MACE
Discharge LLT	13 248	838 (6.3)	0.94 (0.75 to 1.19)	0.60	0.96 (0.76 to 1.21)	0.72
Non-discharge LLT	1181	78 (6.6)	Reference		Reference

Patients who reached the endpoint (stroke recurrence or MACE, death and loss to follow-up) during hospitalisation were excluded.

MACE, major adverse cardiovascular events.